Mycobutin (Rifabutin)

Rifabutin, the active ingredient in Mycobutin, is a rifamycin presented as an oral tablet for oral use. It is employed in the treatment of Mycobacterium avium complex (MAC) infection and as part of combination therapy for tuberculosis in adults and children. It is indicated for patients with confirmed MAC disease and for those requiring adjunctive therapy in multidrug‑resistant tuberculosis regimens.

GNH USA supplies Mycobutin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and timely delivery to meet global healthcare needs.

Rifabutin is a rifamycin antibiotic used to treat infections caused by mycobacteria.

Mycobacterium avium complex (MAC) infection: reduces bacterial burden and improves clinical symptoms. Pulmonary tuberculosis (as part of combination therapy): enhances bacterial clearance when used with other anti‑TB agents. Extrapulmonary tuberculosis (as part of combination therapy): contributes to treatment of disseminated or meningeal TB.

Rifabutin may cause a range of adverse reactions, from mild to severe. Monitoring patients for these events is essential during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, often transient. - Abdominal pain: crampy discomfort in the upper abdomen. - Rash: erythematous skin eruptions, usually self‑limiting. - Neutropenia: mild reduction in white blood cells. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring discontinuation. - Severe neutropenia or agranulocytosis: marked drop in neutrophils, increasing infection risk. - Hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or uveitis. - Hemolytic anemia: rare destruction of red blood cells. - Peripheral neuropathy: tingling or numbness in extremities.

Before initiating Rifabutin therapy, clinicians should evaluate patient history and monitor specific parameters.

Assess liver function before initiating therapy: obtain baseline transaminases and monitor periodically. Monitor complete blood count: watch for neutropenia or agranulocytosis during treatment. Avoid use in patients with known hypersensitivity to rifamycins: discontinue if allergic reaction occurs. Use with caution in patients receiving antiretroviral therapy: potential pharmacokinetic interactions may require dose adjustment. Pregnancy and breastfeeding: risk unknown, weigh benefits against potential fetal or infant harm. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Rifabutin interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Macrolide antibiotics (e.g., clarithromycin): increased rifabutin plasma concentrations. - Protease inhibitors (e.g., ritonavir): may markedly raise rifabutin levels. - Antiretroviral agents (e.g., efavirenz): can reduce rifabutin exposure, compromising efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may elevate rifabutin concentrations, requiring dose adjustment. - Warfarin: rifabutin can alter INR, necessitating more frequent coagulation monitoring. - Oral contraceptives: rifabutin may reduce hormonal effectiveness; advise alternative contraception.